Rein Therapeutics, Inc. Common Stock Shares Outstanding

• Rein Therapeutics, Inc. showed an increase of +27.2% in Common Stock Shares Outstanding from 2024 to 2025.
• This data is from Rein Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
• XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Quarterly values from 10-Q filings: Q2 2017: 450,937 shares | Q3 2017: 14.72 million shares | Q1 2018: 14.73 million shares | Q2 2018: 14.74 million shares | Q3 2018: 14.74 million shares | Q1 2019: 14.88 million shares | Q2 2019: 26.71 million shares | Q3 2019: 27.81 million shares | Q1 2020: 27.81 million shares | Q2 2020: 39.26 million shares | Q3 2020: 39.87 million shares | Q1 2021: 90.21 million shares | Q2 2021: 90.53 million shares | Q3 2021: 90.57 million shares | Q1 2022: 90.82 million shares | Q2 2022: 90.82 million shares | Q3 2022: 90.82 million shares | Q1 2023: 4.54 million shares | Q2 2023: 4.54 million shares | Q3 2023: 4.54 million shares | Q1 2024: 16.84 million shares | Q2 2024: 21.63 million shares | Q3 2024: 21.67 million shares | Q1 2025: 22.01 million shares | Q2 2025: 23.05 million shares | Q3 2025: 25.14 million shares.
• Over the full 10 years of available data (2016 to 2025), Rein Therapeutics, Inc.'s Common Stock Shares Outstanding has grown by 6,271.3%.
• Historical annual values: Fiscal year 2025: 27.55 million shares | Fiscal year 2024: 21.67 million shares | Fiscal year 2023: 4.89 million shares | Fiscal year 2022: 4.54 million shares | Fiscal year 2021: 4.53 million shares | Fiscal year 2020: 43.80 million shares | Fiscal year 2019: 27.81 million shares | Fiscal year 2018: 14.75 million shares | Fiscal year 2017: 14.72 million shares | Fiscal year 2016: 432,413 shares.
• Data sourced from SEC EDGAR public filings as of August 10, 2026.

Last verified: August 10, 2026